Rise Advisors’s Roivant Sciences ROIV Stock Holding History

Rise Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,242	Closed	-$18.8K	–	1159
2025 Q3	$18.8K	Hold	1,242	–	–	0.01%	616
2025 Q2	$14K	Hold	1,242	–	–	0.01%	782
2025 Q1	$12.5K	Buy	+1,242	New	+$13.4K	0.01%	824

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Rise Advisors's ROIV Position: Q4 2025 in Review

Rise Advisors sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 1,242 shares — an estimated $18.8K sold.

Rise Advisors first reported a position in ROIV in Q1 2025 and held it in 3 quarters. The position peaked at $18.8K in Q3 2025. 396 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

Rise Advisors reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 1,242 Roivant Sciences shares in Q4 2025, an estimated $18.8K.
Rise Advisors first reported a position in Roivant Sciences in Q1 2025 and held it in 3 quarters.
Rise Advisors's Roivant Sciences position peaked at $18.8K in Q3 2025.
396 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.